Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

3 of 0 completed with results

Key Signals

3 with results

Data Visualizations

Phase Distribution

3Total
P 2 (3)

Trial Status

Active Not Recruiting3

Clinical Trials (3)

Showing 3 of 3 trials
NCT04340843Phase 2Active Not Recruiting

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

NCT01267955Phase 2Active Not Recruiting

Vismodegib in Treating Patients With Advanced Chondrosarcomas

NCT04458922Phase 2Active Not Recruiting

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

Showing all 3 trials

Research Network

Activity Timeline